Cha Therapeutics aims to improve cancer outcomes by combining immune checkpoint inhibitors (ICIs) with its proprietary epigenetics-plus platform. Our first-in-class epigenetic disruptor, CHA1, targets hematologic malignancies, breast cancer, and solid tumors. CHA1 is designed to enhance ICI efficacy in "cold"tumors that resist treatment, priming them for stronger ICI responses. We are developing Cha1 for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), diseases with an epigenetic etiology that primarily affect elderly patients in urgent need of patient-friendly treatments. The proof-of-concept was developed with ~$10M in non-dilutive funding while the CEO was a professor/breast cancer researcher. With extensive pre-clinical results and promising first-in-human safety/efficacy data, Cha Therapeutics is now in the IND-enabling phase. We will leverage 505(b)(2) expedited IND mechanisms and orphan drug designation to accelerate clinical access to cancer patients.